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Rheumatoid arthritis is characterised by a chronic inflammatory response resulting in destruction of the joint and significant
pain. Although a range of treatments are available to control disease activity in RA, bone destruction and joint pain exist
despite suppression of inflammation. This study is aimed at assessing the effects of parthenolide (PAR) on paw
inflammation, bone destruction, and pain-like behaviour in a mild collagen antibody-induced arthritis (CAIA) mouse
model. CAIA was induced in BALB/c mice and treated daily with 1mg/kg or 4mg/kg PAR. Clinical paw inflammation
was scored daily, and mechanical hypersensitivity was assessed on alternate days. At end point, bone volume and swelling
in the paws were assessed using micro-CT. Paw tissue sections were assessed for inflammation and pre-/osteoclast-like
cells. The lumbar spinal cord and the periaqueductal grey (PAG) and rostral ventromedulla (RVM) regions of the brain
were stained for glial fibrillary acidic protein (GFAP) and ionised calcium-binding adaptor molecule 1 (IBA1) to assess for
glial reactivity. Paw scores increased in CAIA mice from days 5-10 and were reduced with 1mg/kg and 4mg/kg PAR on
days 8-10. Osteoclast-like cells on the bone surface of the radiocarpal joint and within the soft tissue of the hind paw
were significantly lower following PAR treatment (p < 0:005). GFAP- and IBA1-positive cells in the PAG and RVM were
significantly lower following treatment with 1mg/kg (p < 0:0001 and p = 0:0004, respectively) and 4mg/kg PAR (p < 0:0001
and p = 0:001, respectively). In the lumbar spinal cord, IBA1-positive cells were significantly lower in CAIA mice treated
with 4mg/kg PAR (p = 0:001). The findings indicate a suppressive effect of both low- and moderate-dose PAR on paw
inflammation, osteoclast presence, and glial cell reactivity in a mild CAIA mouse model.
1. Background
Rheumatoid arthritis (RA) is a chronic systemic disorder
characterised by joint inflammation, synovial hyperplasia,
and associated destruction of the cartilage and bone. Pain is
associated with this joint destruction and is one of the most
debilitating symptoms reported by RA patients [1, 2]. The
pathogenesis of RA involves chronic infiltration of
immune cells into the synovial joints and production of
proinflammatory cytokines including tumour necrosis fac-
tor alpha (TNF-α), interleukin-1 beta (IL-1β), and
interleukin-6 (IL-6) [3]. These cytokines not only prolong
the inflammatory response within the synovial joints, but
their overproduction promotes bone destruction [4, 5].
The inflammatory cytokines mentioned above have been
shown to sensitise peripheral nerves, resulting in increased
pain sensitivity [6]. Further to this, glial cells have been iden-
tified as being key drivers behind central sensitisation and
hypersensitivity in chronic inflammatory states [7]. The
development of mechanical hypersensitivity has previously
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been reported in mice with inflammatory arthritis, with an
increased glial cell number also observed [8]. However,
mechanical hypersensitivity was observed prior to signs of
inflammation, suggesting that the timing of inflammation
and pain in RAmay not necessarily coincide [8]. Exaggerated
pain, known as hypernociception can persist in RA even in
the absence of clinical symptoms [9]. The disconnect
between the presence of pain in the absence of peripheral
inflammation, as observed in RA, supports the new neuroim-
mune body of evidence (as reviewed by Grace et al. [10]).
Currently, disease-modifying antirheumatic drugs
(DMARDs) target inflammation, allowing chronic bone
erosion to progress. Direct targeting of osteoclast differentia-
tion has been shown to slow the progression of bone erosion
in RA patients [11]; however, inflammation of the synovial
joints ensued. To date, there are limited studies which have
assessed the effect of anti-inflammatory treatments on
inflammation, joint destruction, and glial reactivity in RA
pathogenesis, simultaneously.
Parthenolide (PAR) is a sesquiterpene lactone found in
the Asterceae family of medicinal plants, including feverfew
[12], and is reported to have anticancer as well as anti-
inflammatory, antibone resorptive, and antinociceptive
actions in both in vitro and in vivo models [13–16]. In vitro,
PAR has been shown to prevent osteoclast formation and
bone resorption [17], as well as inhibit the effects of IL-1β
and TNF-α on human chondrocytes [18], which are key
driving factors of RA pathogenesis. In vivo studies have
shown that PAR (0.5 and 1mg/kg) blocks LPS-induced
osteolysis [17] and inhibits wear particle-induced surface
bone loss in murine calvarial models [19]. Within a
collagen-induced arthritis (CIA) rat model, PAR 1mg/kg
reduced inflammation and pannus formation [18]. Of note,
no clear reduction in bone erosion was found andmechanical
hypersensitivity was not investigated [18]. In a clinical trial in
migraine sufferers, PAR was found to have no major safety
concerns [20], although further studies are warranted.
To our knowledge, current studies have not yet investi-
gated the effect that PAR has, directly or indirectly, on the
central nervous system and pain, within a collagen
antibody-induced arthritis (CAIA) mouse model. Therefore,
the current study was aimed at investigating whether PAR
(low and moderate dose) would reduce inflammation, bone
loss, mechanical hypersensitivity, and glial reactivity in a
mild CAIA mouse model.
2. Methods
This study was approved by the Animal Ethics Committee of
the University of Adelaide (M-2015-255) and complied with
the National Health and Research Council (Australia) Code
of Practice for Animal Care in Research and Training
(2014). Mice were housed in approved conditions on a
12-hour light-dark cycle. Food and water were provided
ad libitum and mice were provided with waterproof soft
rubber matting as bedding prior to disease induction.
2.1. Collagen Antibody-Induced Arthritis Model. Thirty-two
female BALB/c mice aged six to eight weeks were obtained
from the University of Adelaide Laboratory Animal Services
and randomly allocated to control (no arthritis or treatment),
CAIA (arthritis with no treatment), CAIA+PAR 1mg/kg
(arthritis treated with 1mg/kg PAR), and CAIA+PAR
4mg/kg (arthritis treated with 4mg/kg PAR).
Arthritis was induced by an intravenous injection, via the
tail vein, with 150μl (1.5mg/mouse) of a cocktail of anti-type
II collagen monoclonal antibodies (Arthrogen-CIA Arthrito-
genic Monoclonal Antibodies, Chondrex Inc., Redwood,
WA, USA), followed by an intraperitoneal injection of 20μl
(10μg/mouse) of E. coli lipopolysaccharide (LPS) on day 3,
as previously described [21–23]. Control animals were
injected with 200μl phosphate-buffered saline (PBS) at both
time points.
PAR (Enzo Life Sciences, Inc., Sapphire Bioscience,
NSW, Australia) was administered at 1mg/kg in 200μl of
10% DMSO in PBS [18], or at 4mg/kg in 200μl of 0.8%
DMSO in PBS via intraperitoneal injection, daily on alternat-
ing sides, from day 4 to day 10. Mice were monitored daily
for body weight and factors of general health using an
approved clinical record sheet for arthritis studies. Clinical
paw swelling was examined daily for the presence of redness,
tenderness, swelling, and inflammation in all paws, by two
blinded observers, using a previously described clinical paw
scoring method [22, 24].
2.2. Assessment of Mechanical Hypersensitivity. Mechanical
hypersensitivity was assessed in the hind paws using the
von Frey paw withdrawal test on alternate days (i.e., days
2, 4, 6, 8, and 10) as BALB/c mice develop a tolerance to
the behavioural test [8, 25]. Mice were placed in plastic
cages with a wire mesh bottom to allow full access to
the hind paws, and behavioural accommodation was
allowed for 15 minutes. Behavioural testing followed the
previously published Dixon up-down method, and the
50% paw withdrawal threshold was calculated [25]. The
hind paw with the lowest 50% probability of paw with-
drawal was identified for examination of mechanical
hypersensitivity as the severity of inflammation between
paws can differ following CAIA induction [22, 23].
2.3. Microcomputed Tomography Analysis. On day 11, trans-
cardial perfusions were performed under anaesthetic
(175mg/kg sodium pentobarbital) using 4% paraformalde-
hyde. Brain, spinal cord, and paw tissues were then collected
and underwent postfixation for 48 hours for micro-CT and
histopathological assessment.
Bone volume (BV) and paw volume (PV, indicator of soft
tissue swelling) of the front and hind paws were assessed
using a microcomputed tomography (micro-CT) scanner
(SkyScan 1076, Bruker, Kontich, Belgium) [22, 26]. The scan
settings were as follows: X-ray source voltage 55 kV, current
180μA, isotropic pixel size 8.5μm, 0.5mm thick aluminium
filter, 0.6 rotation step, frame averaging of 1, and scan time of
35 minutes. Cross-sectional images of all paws were recon-
structed (N-Recon software, Bruker, Kontich, Belgium),
saved in 8-bit format and realigned with the long axis of each
paw along the inferior-superior direction of the images
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(Dataviewer, Bruker, Kontich, Belgium), as previously
described [26].
For front paws, a cylindrical volume of interest (VOI;
4.5mm diameter, 2.4mm length) was used over 280 con-
tiguous cross sections, starting 200 cross sections
(1.7mm) distally to the growth plate of the radiocarpal
joint and extending to 80 cross sections (0.68mm) proxi-
mally, for analysis of bone and soft tissues [22]. In the
hind paws, 600 cross sections (5.1mm length), extending
from the posterior surface of the calcaneus through the
proximal tarsal and metatarsal bones, were used for BV
analysis, along with a polygonal VOI traced around the
calcaneus, tarsal and metatarsal bones, excluding the tibia
and fibula. PV analysis used a cylindrical VOI, with 200
cross sections (5.5mm diameter, 1.7mm length), extend-
ing from the most posterior aspect of the metatarsal
bones, excluding the calcaneus and including the cuboid.
For these VOIs, BV (mm3) and PV (mm3) were quantified
in 3D using uniform thresholding (CT Analyser software,
V1.15.40, Bruker) [22, 26].
2.4. Histological Analysis of the Radiocarpal Joints and Hind
Paws. Front and hind paws were decalcified using 10% ethyl-
ene diaminetetraacetic acid (EDTA), processed into paraffin
and sagittal sections cut (5μm) for routine haematoxylin
and eosin (H&E) and tartrate resistant-acid phosphatase
(TRAP) staining. Histological evaluation of H&E sections
for the presence of inflammatory cells, cartilage and bone
degradation, and pannus formation was carried out using
a previously published semiquantitative scoring method
[27, 28].
The number of multinucleated TRAP-positive cells
(>3 nuclei) was counted in a consistent region of interest
(2.16mm2), to include cells found on the bone surface [27]
and within the surrounding soft tissue of the r joints and hind
paws [22].
2.5. Histological Analysis of Spinal Cord and Brain Tissue.
Immunohistochemical detection of glial fibrillary acidic
protein (GFAP) and ionised calcium-binding adaptor
molecular 1 (IBA1) was conducted on serial coronal sec-
tions (5μm) of the lumbar spinal cord (L3-L5) and brain.
Sections were dewaxed and dehydrated in 100% ethanol,
before endogenous peroxidase activity was removed by
0.5% hydrogen peroxidase. Slides were washed in 1x PBS
(pH7.4, 2 × 5 minutes) for GFAP and 1x PBS+0.3% Triton
X (BOH Chemicals, Australia, 2 x 5 minutes) for IBA1.
Following heat-mediated antigen retrieval in citrate
(0.1mol/l, pH6.0), nonspecific binding was blocked by
3% normal horse serum (NHS; Sigma-Aldrich) for 30
minutes. Primary antibodies (GFAP; Dako 72.5μg/ml, cat-
alogue #Z0334 and IBA1; Wako 0.05μg/μl, catalogue
#019-19741) diluted in 3% NHS were incubated overnight
at room temperature, followed by incubation with a sec-
ondary goat biotinylated anti-rabbit IgG antibody (6μg/ml;
Vector Laboratories) for 30 minutes. Following 1x PBS/1x
PBS+0.3% Triton X wash, slides were incubated with
streptavidin peroxidase conjugate (2μg/ml; ThermoFisher
Scientific) and developed with diaminobenzidine and
counterstained with haematoxylin [29].
IBA1-positive cells were counted within the lumbar
spinal cord (0.38mm2 region of interest) by a blinded
observer. Positive cells were also counted in the PAG
(2.72mm2 region of interest) and RVM (0.079mm2 region
of interest) regions in the brain, as these regions have been
demonstrated to contribute to nociceptive processing [30, 31].
GFAP-positive cells were counted in the same regions of the
lumbar spinal cord and brain using the software Fiji and
colour deconvolution method [32] and a threshold of
125 ± 5 pixels2 and 100 ± 5 pixels2, respectively.
2.6. Statistical Analysis. Statistical analysis utilised GraphPad
Prism® software (V7.03; GraphPad Software, La Jolla, CA,
USA) and SPSS Statistics (V25; IBM SPSS Software, NSW,
Australia). Paw inflammation was assessed using two-way
ANOVA. For von Frey analysis, a linear mixed-effects model
was performed and for repeated measurement over time
using a variance component covariance structure. Assump-
tions of a linear model were found to be upheld by inspec-
tion of histograms and scatter plots of residuals and
predicted values. An interaction of group (1= control,
2 =CAIA, 3=CAIA+PAR 1mg/kg, and 4=CAIA+PAR
4mg/kg) and day (day of test) was included. For micro-
CT and paw and brain histology data, differences among
groups were analysed using the nonparametric Kruskal-
Wallis test and if significant, differences between two
groups were analysed using the Mann-Whitney U test.
Area under the curve (AUC) analysis was conducted on
lumbar spinal cord cell counts. Statistical significance was
assessed post hoc using t-tests between groups. All values
shown are mean ± standard error of the mean (SEM), and
the significance level was set to p < 0:05.
3. Results
3.1. Assessment of Local Paw Inflammation and Mechanical
Hypersensitivity. Induction of CAIA resulted in significant
redness, tenderness, and inflammation in all paws of disease
groups following LPS administration on day 3 (Figure 1(a)).
CAIA mice exhibited significantly greater paw scores
compared to control mice from day 5 to day 10 (p < 0:0003;
Figure 1(b)). On days 8, 9, and 10, PAR 4mg/kg-treated mice
had significantly lower paw scores compared to CAIA
mice (p = 0:041, p = 0:019, and p = 0:017, respectively;
Figure 1(b)). On day 10, PAR 1mg/kg-treated mice also
had significantly lower paw scores compared to CAIA
mice (p = 0:032; Figure 1(b)). There was no significant dif-
ference in paw withdrawal thresholds between control and
CAIA mice, as well as between CAIA mice and PAR
1mg/kg and 4mg/kg- treated mice (Figure 1(c)).
3.2. Micro-CT Analysis of Bone Volume (BV) and Paw
Volume (PV). BV measured in the radiocarpal joints was sig-
nificantly lower in CAIA mice (1:05 ± 0:05mm3) compared
to control mice (1:24 ± 0:05mm3; p = 0:017; Figures 2(a)
and 2(b)). PAR 1mg/kg- (0:98 ± 0:04mm3) and 4mg/kg-
(0:93 ± 0:04mm3) treated mice tended to have slightly lower
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BV in the radiocarpal joint compared to CAIA mice, how-
ever, this was not statistically significant.
BV in the hind paws was significantly lower in
CAIA mice (3:64 ± 0:08mm3; p = 0:01) and PAR
1mg/kg- (3:40 ± 0:07mm3; p = 0:0004) and 4mg/kg-
(3:30 ± 0:07mm3; p = 0:0001) treated mice, compared to
control mice (3:98 ± 0:14mm3; Figure 2(c)). PAR 4mg/kg-
treated mice had significantly lower BV compared to CAIA
mice in the hind paw (p = 0:004; Figure 2(c)). There was evi-
dence of pitting visually observed on the 3Dmicro-CT images
of the navicular bone of the hind paws (Figure 3) of CAIA
groups both with and without PAR treatment.
CAIA mice (37:14 ± 2:07mm3) had a significantly higher
PV in the radiocarpal joint compared to control mice
(24:17 ± 0:82mm3, p < 0:0001; Figure 2(d)). PAR 1mg/kg-
and 4mg/kg- treated mice showed lower PV measurements
in the radiocarpal joint (34:74 ± 2:05mm3 and 34:94 ± 1:75
mm3, respectively) compared to CAIA mice. However, this
was not significantly different (Figure 2(d)). There was no dif-
ference in PV between PAR treatment groups.
A significant increase in PV was also observed in the hind
paws of CAIA mice (24:70 ± 0:53mm3) and PAR 1mg/kg-
(25:61 ± 0:57mm3) and 4mg/kg- (24:65 ± 0:93mm3) treated
mice, compared to control mice (13:15 ± 0:33mm3; p <
0:0001; Figure 2(e)). There was no significant difference in
PV measured in the hind paws between CAIA and PAR
treatment groups nor between the PAR 1mg/kg and 4mg/kg
treatment groups.
3.3. Histological Analysis of the Radiocarpal Joint and Hind
Paws. Representative images of H&E staining in the radiocar-
pal joint are presented in Figure 4(a). Although PAR 1mg/kg
or 4mg/kg treatment groups exhibited reduced scores for cel-
lular infiltration, cartilage and bone degradation, and pannus
formation compared to CAIA mice in the radiocarpal joint,
this was not statistically significant (Figure 4(b)). Similarly,
there was no significant difference in histological scores in
the hind paws between all CAIA and PAR treatment groups
(Figure 4(c)).
A significantly greater number of multinucleated TRAP-
positive cells were observed on the bone surface and in the
surrounding soft tissue of all paws in CAIA and PAR
treatment groups compared to control mice (p < 0:0001;
Figures 5(a)–5(e)). PAR 4mg/kg-treated mice had a signifi-
cantly lower number of multinucleated TRAP-positive cells
on the bone surface of the radiocarpal joint compared to
CAIA mice (p = 0:04; Figure 5(b)) and also had a reduced
number of multinucleated TRAP-positive cells within the
surrounding soft tissue compared to both CAIA mice and
PAR 1mg/kg-treated mice, however, this was not statistically
Control CAIA + PAR 4 mg/kgCAIA CAIA + PAR 1 mg/kg
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Figure 1: Evaluation of local inflammation and mechanical hypersensitivity of mouse paws: (a) representative macroscopic appearance of the
front paws at day 7 postarthritis induction; (b) average paw scores of each group over the 10-day model. Control mice had a paw score of 0 at
each time point; (c) mean tactile paw withdrawal threshold of each group on alternate days throughout the 10-day model. Error bars represent
SEM (n = 8 mice per control, CAIA+PAR 1mg/kg, and CAIA+PAR 4mg/kg; n = 6 mice per CAIA; ∗p < 0:05).
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significant (Figure 5(c)). PAR 4mg/kg-treated mice had a
lower number of multinucleated TRAP-positive cells on the
bone surface of the hind paw compared to PAR 1mg/kg-
treated mice, however, this was not statistically significant
(Figure 5(d)). Within the surrounding soft tissue of the hind
paw, PAR 1mg/kg- and 4mg/kg-treated mice had signifi-
cantly lower numbers of multinucleated TRAP-positive cells
compared to CAIA mice (p = 0:025 and p = 0:006, respec-
tively; Figure 5(e)). However, there was no significant differ-
ence between PAR treatment groups.

















































































































































































Figure 2: Assessment of bone volume (BV) and paw volume (PV) in mouse paws by high-resolution micro-CT: (a) three-dimensional micro-
CT models of the radiocarpal joint and surrounding soft tissue (indicated in red) in the right paw. White arrows represent soft tissue volume
for control. Yellow arrows represent the soft tissue volume for each disease group and highlight the difference in soft tissue and volume
observed. Mean BV in the radiocarpal joint and hind paw (b and c, respectively) and mean PV in the radiocarpal joint and hind paw
(d and e, respectively) expressed in mm3, as assessed by micro-CT analysis at day 11. Error bars represent SEM (n = 16 paws per
control, CAIA+PAR 1mg/kg, and CAIA+PAR 4mg/kg; n = 12 paws per CAIA; ∗p < 0:05, ∗∗∗p = 0:0001, ∗∗∗∗p < 0:0001 compared to
control; ##p = 0:04 compared to CAIA).
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3.4. Histological Analysis of Glial Cells
3.4.1. GFAP Expression within the Central Nervous System.
Representative images of GFAP staining within the lumbar
region of the spinal cord and PAG are represented in
Figures 6(a) and 6(b), respectively. A significantly greater
number of GFAP-positive cells were observed in the lumbar
spinal cord, PAG, and RVM in CAIA mice compared to
control mice (p = 0:003, p < 0:0001, and p = 0:007, respec-
tively; Figures 6(c)–6(e)). A significant reduction in the
number of GFAP-positive cells in the PAG were observed in
PAR 1mg/kg- (41:73 ± 3:90 cells/mm2) and 4mg/kg-
(32:72 ± 1:98 cells/mm2) treatedmice, in comparison to CAIA
mice (65:76 ± 5:26 cells/mm2, p < 0:0001; Figure 6(d)). The
decrease in GFAP-positive cells in PAR 4mg/kg-treated
mice was significantly greater than that in PAR 1mg/kg-
treated mice (p = 0:024; Figure 6(d)). There was also a sig-
nificantly lower number of GFAP-positive cells in the RVM
in PAR 1mg/kg- (275:8 ± 30:39 cells/mm2) and 4mg/kg-
(284:8 ± 25:69 cells/mm2) treated mice, compared to CAIA
mice (433:0 ± 40:31 cells/mm2, p = 0:004 and p = 0:0013,
respectively; Figure 6(e)).
3.4.2. IBA1 Expression within the Central Nervous System.
Representative images of IBA1 staining within the lumbar
spinal cord and PAG are represented in Figures 7(a) and
7(b), respectively. CAIA mice had a significantly greater
number of IBA1-positive cells in the lumbar spinal cord,
PAG, and RVM compared to control mice (p < 0:0007,
p < 0:0001, and p < 0:007, respectively; Figures 7(c)–7(e)).
There was a significantly lower number of IBA1-positive
cells in the lumbar spinal cord in PAR 4mg/kg-treated
mice (122:1 ± 8:107 cells/mm2) compared to CAIA mice
(188:5 ± 18:02 cells/mm2, p = 0:0013; Figure 7(c)). A signifi-
cant decrease in IBA1-positive cells in the PAG was observed
in PAR 1mg/kg- (15.83± 0.72 cells/mm2) and 4mg/kg-
(13.25± 0.86 cells/mm2) treated mice, compared to CAIA
mice (21:28 ± 1:59 cells/mm2, p = 0:0044 and p < 0:0001,
respectively; Figure 7(d)). A significantly lower number of
IBA1-positive cells were also observed in PAR 4mg/kg-
treated mice compared to PAR 1mg/kg-treated mice
(p = 0:0172; Figure 7(d)). Additionally, there was a significant
reduction in IBA1-positive cells in the RVM in PAR 1mg/kg-
(51:58 ± 2:80 cells/mm2) and 4mg/kg- (49:33 ± 3:00
cells/mm2) treated mice, in comparison to CAIA mice
(62:98 ± 3:90 cells/mm2, p = 0:0260 and p = 0:0097, respec-
tively; Figure 7(e)).
4. Discussion
This study utilised the commercially available and well-
established CAIA mouse model which rapidly initiates path-
ogenic features similar to those found in RA [23]. A milder
form of the disease was induced based on previous studies
within our laboratory [21, 26]. Paw inflammation was pres-
ent in the mild CAIA model, as evidenced by significantly
greater paw scores compared to nondiseased controls from
days 5 to 10. These paw scores were greatest at day 8, consis-
tent with the previously reported timeline of disease [23].
Paws remained inflamed at the conclusion of the model as




Figure 3: Representative three-dimensional micro-CT models of the hind paw showing pitting in the navicular: (a) superior view of left hind
paws from the control (first column), CAIA (second column), CAIA+PAR 1mg/kg (third column), and CAIA+PAR 4mg/kg groups (fourth
column). Orange boxes identify the navicular which is presented at greater magnification (b) to emphasise the pitting present in this bone.
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shown by significantly greater PV in CAIA mice compared
with control when assessed by ex vivo micro-CT. As
expected, the mild CAIA model resulted in mild joint
destruction and significantly lower BV in the radiocarpal
joint and hind paws when compared to nondiseased controls.
Glial reactivity was increased within the CAIA mice in both
the spinal and supraspinal region, indicating that the model
was not only able to form an inflammatory model peripher-
ally but also has a central neuroimmune impact.
The current study found that PAR administered daily at
1mg/kg and 4mg/kg significantly reduced local inflamma-
tion in all paws of CAIA mice. PAR 4mg/kg reduced local
inflammation compared to CAIA mice from day 6 and was
reduced even further from days 8 to 10. PAR 1mg/kg had a
lesser effect on local inflammation, as evidenced by paw
scores on days 8 and 9. At day 10, levels of local inflammation
were the same in both PAR-treated groups.
Micro-CT analysis of PV, as an objective measure of
inflammation, was consistent with paw scores at end point.
PV in CAIA mice were similar to PAR 1mg/kg- or
4mg/kg-treated mice, with PV being slightly lower in the
radiocarpal joint in PAR-treated mice compared to CAIA
mice, however, not significantly so. Although not significant,
PV in the hind paws was slightly higher in PAR 1mg/kg-
treated mice. This was unexpected but could be attributed
to the large variability in paw inflammation in response to
Control CAIA








































































































Figure 4: Histological assessment of the radiocarpal joint and hind paws: (a) representative haematoxylin and eosin- (H&E-) stained images
of the radiocarpal joint (20x magnification; scale bars represent 100μm). Semiquantitative analysis of inflammatory cell infiltration, cartilage
and bone degradation, and pannus formation in H&E-stained sagittal sections of the radiocarpal (b) and hind paws (c). Error bars represent
SEM (n = 16 paws per control, CAIA+PAR 1mg/kg, and CAIA+PAR 4mg/kg, n = 12 paws per CAIA; ∗∗∗p < 0:0005 and ∗∗∗∗p < 0:0001
compared to control).
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the systemic administration of CAIA and PAR, as well as the
lower levels of inflammation measured at endpoint in all
CAIA groups.
Histological analysis of the radiocarpal joints and hind
paws at endpoint also supported a reduction in local inflam-
mation following treatment with PAR. A reduction in
inflammatory cell infiltration and pannus formation was
observed to be lower in PAR-treated mice compared to CAIA
mice, however, no difference was observed between PAR
1mg/kg- and 4mg/kg-treated mice. This was unexpected,
as previous studies have shown PAR 1mg/kg to inhibit the
proinflammatory effects of TNF-α and IL-1β, resulting in a
reduction in inflammation and pannus formation in the
synovial joints of hind paws in CIA rats [18].

















































































































































































































Figure 5: Histological assessment of osteoclast-like cells in the radiocarpal joint and hind paws: (a) representative TRAP-stained images of
the radiocarpal joint (20x magnification; scale bars represent 100μm). Average values of TRAP-positive multinucleated cells on the bone
surface and within the surrounding soft tissue in the radiocarpal joint (b and c, respectively) and the hind paws (d and e, respectively).
Error bars represent SEM (n = 16 paws per control, CAIA+PAR 1mg/kg, and CAIA+PAR 4mg/kg, n = 12 paws per CAIA; ∗∗∗∗p < 0:0001
compared to control; #p < 0:05 compared to CAIA; ##p = 0:006 compared to CAIA).
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PAR 1mg/kg and 4mg/kg treatment did not have an
effect on BV in the front and hind paws of mice, whereas
TRAP-positive multinucleated cells were reduced on the
bone surface of the radiocarpal joint and hind paws in
PAR 1mg/kg-treated mice, with PAR 4mg/kg-treated mice
showing a greater reduction. Although the micro-CT and
histology findings do not support one another, they are
both consistent with a previous study, which showed
PAR treatment to have a significant effect limited to the
bone surface, on reducing bone surface resorption induced
by polyethylene particles in a murine calvarial model of
peri-implant osteolysis, but with no effect on overall BV
[19]. Similarly, within the current study, it is possible that
the suggestive decrease in bone resorption indicated by the
decrease in TRAP-positive cells (on the bone surface) as
seen by microscopic analysis could be partially compen-
sated by the large quantity of bone (volume) analysed by
micro-CT within the radiocarpal joint and hind paws. Fur-
ther quantification of BV of the smaller individual carpal
and tarsal bones in the front and hind paws, respectively,
may be needed to show a reduction in bone loss quantifi-
able volumetrically in terms of BV following PAR treat-
ment in CAIA mice.
The current study found PAR 1mg/kg and 4mg/kg
reduced local paw inflammation, but with no change in over-
all BV in either front or hind paws. This is consistent with a
previous study reporting a reduction in inflammation with
little effect on overall bone loss, by 1mg/kg PAR, in a CIA
rat model [18]. This could be attributed to the low dose of
PAR used in both treatment groups, as in the complex CAIA
model, low-dose PAR may be unable to inhibit both local
inflammation and the subsequent effect inflammation has
on stimulating bone destruction.
PAR treatment did not reduce mechanical hypersensitiv-
ity in CAIA mice, as evidenced by inconsistent paw with-
drawal thresholds. Paw withdrawal thresholds in CAIA
Control CAIA CAIA + 1 mg/kg PAR CAIA + 4 mg/kg PAR
(a)
























































































































































Figure 6: Histological assessment of GFAP-positive cells in the lumbar spinal cord region, PAG, and RVM: (a) Representative GFAP-stained
image of the spinal cord (40x magnification; scale bars represent 50 μm); (b) representative GFAP-stained image of the PAG (40x
magnification; scale bars represent 50μm); (c) area under the curve analysis of the average number of GFAP-positive cells in serial
sections within the lumbar region of the spinal cord. Average number of GFAP-positive cells in the PAG and RVM of the brain (d and e,
respectively). Error bars represent SEM (n = 8 animals per control, CAIA+PAR 1mg/kg, and CAIA+PAR 4mg/kg, n = 6 animals per
CAIA), ∗∗∗∗p < 0:00001, ∗∗p < 0:002, ∗p < 0:03.
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mice remained consistent with nondiseased control thresh-
olds from days 2-8, despite the presence of mild paw inflam-
mation. This is not consistent with a previous study, which
displayed robust mechanical hypersensitivity concomitant
with the onset of joint inflammation in a moderate CAIA
model in BALB/c mice [8]. Within that study, paw with-
drawal thresholds, assessed using von Frey, did not return
to baseline four weeks following the reduction of joint
inflammation [8]. Of note, in the current study, remission
stages were not investigated and the difference observed
between studies may be due to the occurrence of endogenous
analgesia. Previous pain models in mice have examined the
effect of endogenous analgesia where mechanical hypersensi-
tivity assessed via von Frey reached baseline withdrawal
threshold scores; however, this was reversed, upon adminis-
tration of naloxone, an opioid receptor antagonist [33]. This
suggests that latent pain sensitisation may also occur in
inflammatory pain models, such as CAIA. Future studies
should incorporate automated gait analysis such as the cat-
walk assessment [34] when assessing pain-like behaviour
in animal models of inflammatory arthritis as they exam-
ine limb guarding, a common clinical symptom in joint
and neuropathic pain [35]. Additionally, as a spontaneous
pain assessment, gait analysis by the catwalk could exam-
ine more complex decision-making involved in pain more
accurately [35].
Mechanical hypersensitivity was hypothesised to be
reduced in PAR-treated mice due to the reduction in glial
cells observed, as microglia and astrocytes are associated with
neuropathic pain [36, 37]. Findings from Lampa et al. suggest
that nociception from an inflammatory experimental arthri-
tis mouse model was due to changes in both the peripheral
and central nervous system [38]. We propose that peripheral
inflammation promoted central adaption observed via the
increase in glial reactivity within our CAIA model. Kapitzke
et al. 2011 reviewed multiple studies suggesting that opioid
receptors were activated in inflammatory animal models
[39]. Therefore, our increase in glial cells may not have
Control CAIA CAIA + 1 mg/kg PAR CAIA + 4 mg/kg PAR
(a)



























































































































































Figure 7: Histological assessment of IBA1-positive cells in the lumbar spinal cord region, PAG, and RVM: (a) representative IBA1-stained
image of the spinal cord (40x magnification; scale bars represent 50μm); (b) representative IBA1-stained image of the PAG (40x
magnification; scale bars represent 50μm); (c) area under the curve analysis of the average number of IBA1-positive cells on serial
sections in the lumbar region of the spinal cord. Average number of IBA1-positive cells in the PAG and RVM of the brain (d and e,
respectively). Error bars represent SEM (n = 8 animals per control, CAIA+PAR 1mg/kg, and CAIA+PAR 4mg/kg, n = 6 animals per
CAIA), ∗∗∗∗p < 0:00001, ∗∗p < 0:002, ∗p < 0:03.
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aligned with a change in mechanical hypersensitivity due to
peripheral analgesic responses resulting from changes in
peripheral immune effector cells. Our results were suggestive
of PAR acting as a neuroimmune mediator, although this was
not assessed directly.
PAR has previously been shown to be effective at crossing
the blood-brain barrier [40, 41]; however, few studies investi-
gating pain and inflammation have examined glial reactivity
in both the PAG and RVM. Our findings demonstrate that
spinal and brain glial cell reactivity was reduced in PAR-
treated mice. GFAP- and IBA1-positive cells were signifi-
cantly reduced in PAR 1mg/kg- and 4mg/kg-treated mice
compared to CAIA mice in the PAG and RVM. However,
in the lumbar spinal cord, only a significant reduction of
IBA1-positive cells was observed in PAR 4mg/kg-treated
mice. These findings suggest that PAR 1mg/kg and 4mg/kg
was most effective at reducing glial reactivity within the
supraspinal regions of interest, rather than the lumbar spinal
cord in CAIA mice.
Sex-specific differences in both pain perception and glial
reactivity have been observed within CD1 neuropathic
mouse models. Vacca et al. observed that within the lumbar
L4-L5 spinal cord, female mice had an increased reactivity
in astrocytic and microglial cells compared to male mice
[42]. Additionally, Vacca et al. measured mechanical hyper-
sensitivity with results suggesting that female mice took lon-
ger to return to baseline than male mice [42]. Doyle et al.
found that within the PAG, female Sprague Dawley rats
had an increased level of microglia reactivity compared to
males [43]. In future studies, the inclusion of male CAIA
mice would be informative to investigate if sex-specific differ-
ences are present in the CAIA model.
The conflicting findings regarding bone loss and inflam-
mation when compared to past studies [18, 19] may also be
a result of the methodology employed to induce CAIA.
Although the CAIA model has a high penetrance in BALB/c
mice, the joints are randomly affected due to the systemic
administration [23]. Thus, the large mouse variability in
response to both disease and treatment may explain the
results in the current study. There may also be variability
in the absorption and availability of active metabolites of
PAR within the circulation which may have also impacted
the results. As PAR was not assessed in healthy mice, we
are unable to identify the effect of PAR on the central ner-
vous system in the absence of peripheral inflammation.
Additionally, mechanical hypersensitivity should be assessed
prior to the onset of symptoms and following remission
stage as it is more clinically relevant. To achieve a more
effective result in the complex in vivo environment, the
use of an animal model that targets specific joints through
the intra-articular injection of the antigen, as well as the
intra-articular administration of PAR, may provide a better
strategy for future studies.
5. Conclusion
This study demonstrated that PAR, at 1mg/kg or 4mg/kg,
suppressed local inflammation and uniquely demonstrates
the effects of peripheral inflammation on both the spinal
and supraspinal nociceptive processing pathways within a
mild CAIA mouse model. Further investigations involving
new strategies to investigate bone and joint destruction with
glial reactivity complemented by analysis of pain-like behav-
iour in the CAIA mouse model are warranted to clarify the
role of potential therapeutics on RA specific pain, inflamma-
tion, and bone loss.
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